Clinical Trial

Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall Good Health in South Africa.

Study acronym: IAVI G004
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and immunogenicity of mRNAs encoding HIV immunogens (eOD-GT8 60mer, core-g28v2 60mer, N332-GT5 gp151) in adult participants without HIV and in overall good health in South Africa.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-02
Trial Details
NCT Number NCT06694753
Lead Sponsor International AIDS Vaccine Initiative
Collaborators: ModernaTX, Inc., The Scripps Research Institute, National Institute of Allergy and Infectious Diseases (NIAID), Bill and Melinda Gates Foundation
Conditions HIV Infections
Enrollment 96 participants
Start Date 2025-12-15
Primary Completion 2026-12-08 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-01